Business Trends– category –
-
Syntax Bio Cellgorithm: iPSC to Beta Cell Programming in 4 Days
BioSpace USA Overview Syntax Bio has demonstrated the ability to differentiate human induced pluripotent stem cells (iPSC) into pancreatic beta-like cells within four days using its Cellgorithm platform. This programmable approach utiliz... -
Multiply Labs: Robotic Cell Therapy Production and $75M Series B
Tech Arcade USA Overview Multiply Labs has raised $75 million in Series B funding to scale robotic clusters that automate the production of personalized cell therapies. The technology can reduce costs per dose by up to 74% and increase c... -
CRISPR-Edited HLA Liver Transplants: Safety and Feasibility Trial
TrialX USA Overview An early-phase clinical trial is assessing the use of ex vivo CRISPR-Cas9 genome editing on donor liver grafts to create "hypoimmunogenic" organs. By knocking out specific HLA genes to reduce immunogenicity, the study... -
Zanvastro: FDA-approved ASO treatment for Alexander disease
ScienceDaily (University of Wisconsin-Madison) USA Overview The FDA has approved Zanvastro, the first disease-modifying drug for Alexander disease, a rare neurological disorder. Developed through a collaboration between Ionis Pharmaceuti... -
Aglatimagene: Candel Therapeutics NSCLC Phase 2a 2026 roadmap
Trefis USA Overview Candel Therapeutics announced compelling Phase 2a clinical trial results for its investigational non-small cell lung cancer (NSCLC) therapy, aglatimagene besadenovec, demonstrating a median overall survival (OS) of 24... -
Lonvo-z: Intellia Therapeutics’ FDA approval for CRISPR therapy
Vertex AI Search (Biotech News Outlet) USA Overview Intellia Therapeutics' in vivo CRISPR gene therapy, lonvoguran ziclumeran (lonvo-z), has received Biologics License Application (BLA) approval from the U.S. FDA for the treatment of her... -
Sartorius Eveo: Cell therapy costs cut 90% to under $40,000
Onyx Newsroom Germany Overview Sartorius announced at the Cell & Gene Meeting on the Mesa that its automated Eveo Cell Therapy Platform can reduce cell therapy manufacturing costs to under $40,000 per patient. This closed system inte... -
SonoThera’s Non-Viral RIPPLE Gene Therapy Boosts Dystrophin Expression by 290% in Macaques; Clinical Trials Slated for Mid-2027
Endpoints News USA Overview SonoThera, an Endpoints 11 2026 award recipient, is gaining traction with its RIPPLE (Remote Induction of Pulsed Pressure Lateral to Energy) non-viral gene therapy technology. Following a recent $125 million S... -
FDA Approves First AAV Gene Therapy UX111 for Sanfilippo Syndrome Type A, Offering New Hope for Pediatric Neurodegeneration
CheckRare / Rare Disease Research USA Overview The U.S. FDA has approved UX111, the first gene therapy for Sanfilippo Syndrome Type A (MPS IIIA), a rare lysosomal storage disorder characterized by pediatric dementia. This treatment deliv... -
Astellas Advances Hypoimmune iPSC Therapies for Retinal Diseases via Gene-Edited Universal Cell Technology to Overcome Immune Rejection
Astellas Japan Overview Astellas is pioneering gene-edited Universal Cell technology to develop off-the-shelf pluripotent stem cell (PSC)-derived therapies for retinal diseases, aiming to mitigate immune rejection. This technology makes ...
